RT @Biomaven: I previously posted three threads on roxa in NDD - here they are again for any who might have missed them: https://t.co/2XgIp…
I previously posted three threads on roxa in NDD - here they are again for any who might have missed them: https://t.co/2XgIpcdxOE https://t.co/cEOA25k86Z https://t.co/PHemm0wa4L
Clinical awareness of anaemia risk is important in people with newly-identified or progressed #ChronicKidneyDisease https://t.co/ucWUCjFcKJ | Clin Epidemiol #CKD #KidneyDisease
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
Yep, I’m retweeting all three...*if* $FGEN gets approval with a clean label this December then we can finally put all these arguments to bed once and for all and strictly focus on the sales going forward. And how refreshing that will be. Oh, and some pamre
RT @Biomaven: Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough an…
Third thread on $FGEN NDD opportunity. So first, market size. On call yesterday, company said NDD pts with severe enough anemia to treat is around 2.5 million pts in US. That is consistent with recent large survey on CKD pts in Denmark: https://t.co/iuZ